Related references
Note: Only part of the references are listed.Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Kathy S. Albain et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
Juliet Richman et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
Patricia A. Ganz et al.
NPJ BREAST CANCER (2021)
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Iris Noordhoek et al.
CLINICAL CANCER RESEARCH (2021)
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy A Secondary Analysis of the TAILORx Randomized Clinical Trial
Joseph A. Sparano et al.
JAMA ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Philip D. Poorvu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value
Changjun Wang et al.
SCIENTIFIC REPORTS (2020)
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer
Ivana Sestak et al.
CLINICAL CANCER RESEARCH (2020)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
Milan Radovich et al.
JAMA ONCOLOGY (2020)
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials
Iris Noordhoek et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
Johannes Ettl et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial
Cornelia Kolberg-Liedtke et al.
BREAST CANCER RESEARCH (2020)
Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study
Ivana Sestak et al.
CANCER RESEARCH (2020)
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
Maj-Britt Jensen et al.
NPJ BREAST CANCER (2020)
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Elisabeth Trapp et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Ivana Sestak et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer
Mark Jesus M. Magbanua et al.
CLINICAL CANCER RESEARCH (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2019)
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools
Julia Foldi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Isaac Garcia-Murillas et al.
JAMA ONCOLOGY (2019)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Zsuzsanna Varga et al.
SCIENTIFIC REPORTS (2019)
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2019)
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S. J. Luen et al.
ANNALS OF ONCOLOGY (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Maria Vittoria Dieci et al.
SEMINARS IN CANCER BIOLOGY (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
E. J. Blok et al.
CANCER TREATMENT REVIEWS (2018)
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal
Shi-Yi Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer
Anne-Vibeke Laenkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Lvana Sestak et al.
JAMA ONCOLOGY (2018)
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Joseph Sparano et al.
JAMA ONCOLOGY (2018)
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
Mai-Britt Jensen et al.
BREAST CANCER RESEARCH (2018)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
Betty R. Ferrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Yi Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Hege O. Ohnstad et al.
BREAST CANCER RESEARCH (2017)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial
Philip Hepp et al.
ANTICANCER RESEARCH (2016)
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial
John M. S. Bartlett et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Giancarlo Pruneri et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study
Dennis C. Sgroi et al.
BREAST CANCER RESEARCH (2016)
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
Minetta C. Liu et al.
NPJ BREAST CANCER (2016)
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
Eleonor Olsson et al.
EMBO MOLECULAR MEDICINE (2015)
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Circulating tumor cells in non-metastatic triple-negative breast cancer
Mandar Karhade et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Brigitte Rack et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: results from the GEICAM 9906 trial
Miguel Martin et al.
BREAST CANCER RESEARCH (2014)
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Dennis C. Sgroi et al.
LANCET ONCOLOGY (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer et al.
PLOS ONE (2013)
Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
Richard N. Shiffman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2012)
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Anthony Lucci et al.
LANCET ONCOLOGY (2012)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Sonya Blesser Streeter et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
